375 related articles for article (PubMed ID: 29748017)
1. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Reck M; Garassino MC; Imbimbo M; Shepherd FA; Socinski MA; Shih JY; Tsao A; Lee P; Winfree KB; Sashegyi A; Cheng R; Varea R; Levy B; Garon E
Lung Cancer; 2018 Jun; 120():62-69. PubMed ID: 29748017
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Inhibitors in NSCLC.
Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapies in non-small-cell lung cancer.
Alshangiti A; Chandhoke G; Ellis PM
Curr Oncol; 2018 Jun; 25(Suppl 1):S45-S58. PubMed ID: 29910647
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Reck M; Paz-Ares L; Bidoli P; Cappuzzo F; Dakhil S; Moro-Sibilot D; Borghaei H; Johnson M; Jotte R; Pennell NA; Shepherd FA; Tsao A; Thomas M; Carter GC; Chan-Diehl F; Alexandris E; Lee P; Zimmermann A; Sashegyi A; Pérol M
Lung Cancer; 2017 Oct; 112():181-187. PubMed ID: 29191593
[TBL] [Abstract][Full Text] [Related]
6. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.
Cantelmo AR; Dejos C; Kocher F; Hilbe W; Wolf D; Pircher A
Curr Opin Oncol; 2020 Jan; 32(1):44-53. PubMed ID: 31609741
[TBL] [Abstract][Full Text] [Related]
10. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Reck M; Kerr KM; Grohé C; Manegold C; Pavlakis N; Paz-Ares L; Huber RM; Popat S; Thatcher N; Park K; Hilberg F; Barrueco J; Kaiser R
Future Oncol; 2019 Apr; 15(12):1363-1383. PubMed ID: 30758227
[TBL] [Abstract][Full Text] [Related]
11. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
[TBL] [Abstract][Full Text] [Related]
13. New options for combination therapy for advanced non-squamous NSCLC.
Rossi A
Expert Rev Respir Med; 2019 Nov; 13(11):1095-1107. PubMed ID: 31512526
[No Abstract] [Full Text] [Related]
14. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
[TBL] [Abstract][Full Text] [Related]
15. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M
Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Metzenmacher M; Rizzo F; Kambartel K; Panse J; Schaufler D; Scheffler M; Azeh I; Hoiczyk M; Turki AT; Atz J; Buchner H; Hoffmann C; C Christoph D
Future Oncol; 2021 Oct; 17(30):3965-3976. PubMed ID: 34287064
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
[TBL] [Abstract][Full Text] [Related]
19. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Reinmuth N; Heigener D; Reck M
Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Paz-Ares LG; Pérol M; Ciuleanu TE; Kowalyszyn RD; Reck M; Lewanski CR; Syrigos K; Arrieta O; Prabhash K; Park K; Pikiel J; Göksel T; Lee P; Zimmermann A; Carter GC; Alexandris E; Garon EB
Lung Cancer; 2017 Oct; 112():126-133. PubMed ID: 29191585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
